DevCurationThe Premier Voice of the Entire Tech Ecosystem
Home
Where the Money Moved
News
Events
Investor Spotlight
Company Spotlight
Frameworks
DevCuration
Home
Where the Money Moved
News
Events
Investor Spotlight
Company Spotlight
Frameworks
DevCuration
Latest
TipHaus Secures Vista Backing for Enterprise Tip Software|Seawolf Therapeutics Raises $100M in Seed and Series A|Corma Raises $125M Series A for Defensive CybersecurityCorma Raises $125M Series A for Defensive Cybersecurity|Betterness Raises $1M to Expand Miami Wellness Networks|Focus Financial Partners Agrees to Apollo Strategic Investment|Knit Health Raises $35M Series A for Clinical AI Deployment|COUNT Raises $6.5M Seed to Expand AI Accounting Platform|Numa Raises $45M Series C for Dealership AI Expansion|Remedy Robotics Raises $62M Series B for N1 Clinical Trials|Alecto Raises $20M Seed for AI-Native Consumer Law|TipHaus Secures Vista Backing for Enterprise Tip Software|Seawolf Therapeutics Raises $100M in Seed and Series A|Corma Raises $125M Series A for Defensive CybersecurityCorma Raises $125M Series A for Defensive Cybersecurity|Betterness Raises $1M to Expand Miami Wellness Networks|Focus Financial Partners Agrees to Apollo Strategic Investment|Knit Health Raises $35M Series A for Clinical AI Deployment|COUNT Raises $6.5M Seed to Expand AI Accounting Platform|Numa Raises $45M Series C for Dealership AI Expansion|Remedy Robotics Raises $62M Series B for N1 Clinical Trials|Alecto Raises $20M Seed for AI-Native Consumer Law
DevCuration

The premier voice of the tech ecosystem, from ideation to enterprise.

Explore

  • Where the Money Moved
  • Events
  • Articles & Analysis

Spotlights

  • Investor Spotlight
  • Company Spotlight
  • Frameworks

Company

  • About Us
  • Privacy Policy
  • Terms of Service
© 2026 DevCuration. All rights reserved.
TwitterLinkedIn
Logos provided by Logo.dev
Back to articles
November 17, 2026
•Jesse LandryJesse Landry

Seawolf Therapeutics Raises $100M in Seed and Series A

Sanofi is taking a place in Seawolf Therapeutics' development work while the San Diego biotech is still building toward a drug candidate. That relationship gives Seawolf's emergence from stealth a second dimension: a pharmaceutical company has agreed to explore treatments using the same DNA delivery platform that venture investors are financing.

Seawolf disclosed $100M in combined seed and Series A funding on November 16, 2026. Versant Ventures led the seed round; the Series A included Versant, MPM BioImpact, Novartis Venture Fund and other investors. Founder, president and CEO Elizabeth Alcamo and CSO Rob Burke are advancing a platform designed to combine durable protein expression with the option to administer another dose.

The company's separate research collaboration and exclusive license agreement with Sanofi covers bleeding disorders and other undisclosed indications. Seawolf could earn up to $1.2B in research, development and commercial milestones, plus tiered royalties. Its own lead program addresses metabolic diseases, giving the platform both an internal development assignment and a pharmaceutical partnership while the supporting evidence remains preclinical.

What the $100M financing covers

The announced $100M spans two funding stages, with no individual seed or Series A amount disclosed. The company's release identifies Versant as the founding investor and seed lead, then names MPM BioImpact and Novartis Venture Fund alongside Versant in the Series A. Eli Lilly and Company, CRISPR Therapeutics, Sixty Degree Capital, Alexandria Venture Investments and Pathway to Cures also participated, together with other unnamed investors.

Pathway to Cures is the National Bleeding Disorders Foundation's philanthropic venture arm, a relevant connection given the Sanofi collaboration's disease focus. Each institution arrives through a distinct relationship: venture financing supplies company capital, pharmaceutical investors participate in the syndicate, and Sanofi has a research and licensing agreement. Keeping those roles visible gives the announcement more substance than a list of recognizable names.

The Sanofi milestone ceiling belongs to a different financial category from the financing already raised. Reuters reported that the agreement includes an upfront payment whose size Alcamo declined to disclose. Future milestone receipts depend on the collaboration's progress, and royalties depend on resulting product sales. Adding $1.2B to the funding headline would turn prospective development economics into an account of money received.

TRIDENT makes delivery part of the treatment design

Seawolf calls its platform TRIDENT, short for Targeted RNA-Induced DNA Expression via Nuclear Translocation. The company's technology description identifies three components: an immune-quiet DNA payload encoding a therapeutic protein, mRNA encoding an auxiliary factor that helps DNA access the nucleus, and a proprietary lipid nanoparticle formulation that carries both. The delivery system has an active role in whether the genetic instructions reach the place where they can be used.

Seawolf is pursuing longer-lasting protein production alongside repeat administration. That combination is the commercial and clinical proposition: a treatment could persist while leaving a physician scope to adjust expression through dosing. Alcamo described individualized titration in a direct interview with Fierce Biotech, explaining why repeat dosing matters to the platform's design. The intended flexibility gives durability a practical relationship to patient management.

For developers and prospective pharmaceutical partners, that also changes what a delivery platform is being asked to provide. A longer interval between administrations is useful only within a treatment that reaches an appropriate expression level and can be managed safely. Seawolf is developing the payload, the carrier and the mechanism for nuclear access together, putting several consequential parts of that assignment inside one research program.

The evidence is still in animals

Seawolf reports therapeutically relevant protein expression in rodents and nonhuman primates, with limited signs of immune activation or liver toxicity in the studies it describes. The company also reports disease-model results involving metabolic and rare diseases. Those are company-reported preclinical findings; the announcement supplies no human efficacy result or approved treatment.

That development stage matters when interpreting both the financing and the partnership. Investors have financed an approach whose value depends on translation from animal experiments into medicines that can be studied in people. A pharmaceutical collaboration adds another party with a reason to investigate the technology, while the experimental work must establish how sustained expression and repeat administration behave in the intended clinical setting.

The company says initial applications express biologics from hepatocytes, the liver's principal cells, with research underway to reach additional organs and cellular targets. That starting point brings useful specificity to a platform described as versatile. Broader applications remain a research direction, and Seawolf's available public evidence does not establish that every proposed tissue or indication is equally accessible.

Two portfolios will ask different questions of the platform

Seawolf's current leadership page identifies Alcamo as president and CEO, Burke as CSO, and Versant managing director Tom Woiwode as board chair. Its scientific organization also includes dedicated leaders for payload engineering, delivery technologies and development sciences. The operating structure reflects the parts of TRIDENT that have to advance together as individual therapeutic programs become more defined.

Reuters reports company targets of selecting a development candidate in late 2027 and filing to begin human studies by the end of 2028. These are expectations rather than completed regulatory milestones. For a reader assessing the November financing, the nearer operating question is how the team advances a metabolic-disease candidate while supporting Sanofi's work in bleeding disorders and additional indications.

The partnership gives Seawolf another route for the platform to enter drug development, with a separate set of targets, decisions and economic incentives. Its internal portfolio gives Alcamo and Burke responsibility for choosing where the company itself will commit development resources. As those programs progress, the same DNA delivery machinery will have to earn its place in treatments built around different proteins, disease needs and dosing decisions.

DevCuration Data

Biotech funding, last 30 days

DevCuration's funding database tracked 16 Biotech rounds totaling $2.1B in disclosed capital over the past 30 days. Recent deals we covered:

  • Sofinnova Partners Closes $815M Crossover II FundFund Final Close · $815M · Nov 16
  • Neurosterix Raises $105M for Schizophrenia Phase 2 PlansSeries B · $105M · Nov 14
  • Araceli Biosciences Raises $4.5M for Cell Imaging Growth$4.5M · Nov 13
  • MaxCyte Plans $151.8M Akron Bio Deal for Cell TherapyM&A · $151.8M · Nov 12
  • Dechra Agrees to Acquire Gallant's Cell-Therapy PlatformNov 10
All tracked rounds

Frequently Asked Questions

How does TRIDENT combine DNA delivery with repeat dosing?

Seawolf describes a lipid nanoparticle carrying DNA that encodes a therapeutic protein and mRNA that encodes a factor helping the DNA enter the nucleus. The platform is designed for sustained expression with repeat administration; available results are preclinical.

How should the Sanofi milestone value be interpreted alongside the financing?

The $100M is the disclosed aggregate seed and Series A financing. The separate Sanofi agreement offers up to $1.2B in contingent research, development and commercial milestones plus royalties. Reuters reports an upfront payment whose amount was not disclosed.

Which development programs are Seawolf and Sanofi pursuing?

Seawolf identifies metabolic diseases as the focus of its proprietary lead program. The Sanofi collaboration covers bleeding disorders and additional undisclosed indications, creating a separate partnered development path.

What evidence supports Seawolf’s approach today?

Seawolf reports protein-expression and tolerability findings in nonhuman primates and results in animal disease models. The announcement does not establish clinical efficacy in people. Reuters reports company targets for candidate selection in late 2027 and a filing to begin human studies by the end of 2028.

Back to all articles
Newsletter

Where the Money Moved

The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.

Subscribe to Where the Money Moved
Seawolf Therapeutics

Seawolf Therapeutics

  • San Diego
WebsiteLinkedIn

Key Executives

  • Elizabeth Alcamo
  • President and CEO; Rob Burke
+1 more (coming soon)

Investors

Versant Ventures
View Career Page

Related Articles

Funding Announcement
Mount Thor Raises $45M for Apple-Based AI Infrastructure
Nov 13, 2026
Funding Announcement
Operand Raises $31M Across Seed and Series A Funding
Nov 12, 2026
Funding Announcement
geniosAI Raises $19.1M Across Seed and Series A Rounds
Nov 9, 2026
Funding Announcement
Healthleap Raises $38M to Expand Inpatient Risk AI
Oct 7, 2026
Funding Announcement
Hike Medical Raises $22.5M for Device-Based Care
Aug 25, 2026

More from Jesse Landry

Funding Announcement
TipHaus Secures Vista Backing for Enterprise Tip Software
Nov 17, 2026
Funding Announcement
Corma Raises $125M Series A for Defensive Cybersecurity
Nov 16, 2026
Funding Announcement
Betterness Raises $1M to Expand Miami Wellness Networks
Nov 16, 2026

Trending

Events
AI Infra Summit 6 Examines Who Pays for Inference at Scale
Nov 16, 2026
News
Serve Robotics Opens Physical AI Services to Outside Fleets
Nov 15, 2026
Company Spotlight
Nebuly Company Spotlight: Building Enterprise AI Measurement
Nov 13, 2026
View all posts